RxSight, Inc. Releases 2025 Third Quarter Results, Narrows Full-Year Revenue Range
Published on November 7, 2025
ALISO VIEJO, Calif.—RxSight, Inc., (Nasdaq: RXST) an ophthalmic medical device company focused on improving vision after cataract surgery, on Wednesday announced financial results for the three months ended September 30, 2025. In the third quarter of 2025, the company reported total revenue was $30.3 million, representing a decrease of 14 percent compared with $35.3 million in Q3 of 2024. During the quarter, light adjustable lenses (LAL) revenue increased 6 percent while light delivery devices (LDD) revenue decreased 69 percent, compared with the third quarter of 2024.